Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
Public ClinicalTrials.gov record NCT00060372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation
Study identification
- NCT ID
- NCT00060372
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 21 participants
Conditions and interventions
Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Childhood Myelodysplastic Syndromes
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Disseminated Neuroblastoma
- Malignant Neoplasm
- Ovarian Choriocarcinoma
- Ovarian Embryonal Carcinoma
- Ovarian Immature Teratoma
- Ovarian Mature Teratoma
- Ovarian Mixed Germ Cell Tumor
- Ovarian Monodermal and Highly Specialized Teratoma
- Ovarian Polyembryoma
- Ovarian Yolk Sac Tumor
- Previously Treated Myelodysplastic Syndromes
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Mantle Cell Lymphoma
- Recurrent Neuroblastoma
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Refractory Chronic Lymphocytic Leukemia
- Refractory Multiple Myeloma
- Relapsing Chronic Myelogenous Leukemia
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage II Ovarian Epithelial Cancer
- Stage III Malignant Testicular Germ Cell Tumor
- Stage III Multiple Myeloma
- Stage III Ovarian Epithelial Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage IV Ovarian Epithelial Cancer
- Testicular Choriocarcinoma
- Testicular Choriocarcinoma and Embryonal Carcinoma
- Testicular Choriocarcinoma and Seminoma
- Testicular Choriocarcinoma and Teratoma
- Testicular Choriocarcinoma and Yolk Sac Tumor
- Testicular Embryonal Carcinoma
- Testicular Embryonal Carcinoma and Seminoma
- Testicular Embryonal Carcinoma and Teratoma
- Testicular Embryonal Carcinoma and Teratoma With Seminoma
- Testicular Embryonal Carcinoma and Yolk Sac Tumor
- Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma
- Testicular Teratoma
- Testicular Yolk Sac Tumor
- Testicular Yolk Sac Tumor and Teratoma
- Testicular Yolk Sac Tumor and Teratoma With Seminoma
Interventions
- ipilimumab Drug
- therapeutic allogeneic lymphocytes Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2003
- Primary completion
- Mar 31, 2008
- Completion
- Not listed
- Last update posted
- Mar 26, 2013
Started 2003
United States locations
- U.S. sites
- 5
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scripps Clinic - La Jolla | La Jolla | California | 92037 | — |
| University of California San Diego | La Jolla | California | 92093-0960 | — |
| Blood and Marrow Transplant Group of Georgia | Atlanta | Georgia | 30342 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Dana-Farber Harvard Cancer Center | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00060372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2013 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00060372 live on ClinicalTrials.gov.